Thus, the rare mutation rate and the ability to activate pyroptotic process of CASP4 in the SCGB3A2-inducded non-canonical inflammasome pathway could be utilized as a new strategy for human cancer therapy. The gene discussed is SCGB3A2; the disease is cancer.